GeNeuro

GeNeuro

Innovating by targeting the cause of diseases potentially mediated by endogenous retroviruses - multiple sclerosis, certain neuropathies, diabetes, schizophrenia. Learn more

Launch date
Employees
Market cap
$2.1m
Enterprise valuation
$15m (Public information from Sep 2024)
Company register number CH-660.0.307.006-3
Geneva Canton of Geneva (HQ)
Authorizing premium user...